Scabies And Lice

Pesticide-Free Lice Treatment Gets FDA Clearance

By July 11, 2017

Resultz is an odorless treatment that kills and removes head lice with a 5 minute application time; this is the shortest time frame associated with currently available lice products.

Parasitic Topical May Aid Skin Inflammation Diseases

January 09, 2017

Ivermectin (IVM) has anti-inflammatory properties that could be beneficial in treatment of T-cell mediated skin inflammatory diseases, according to an experimental study published online in Allergy.

Growing Resistance May Make OTC Head Lice Treatments Obsolete

By September 07, 2016

A literature review of head lice treatments in the U.S. found a significant decline in the effectiveness of over-the-counter (OTC) permethrin and synergized pyrethrins (collectively pyrethroids) treatments, indicating a need for judicious use of effective treatments by clinicians.

Scabies Treatment No Longer Available

By June 02, 2016

Wockhardt/Morton Grove Pharmaceuticals announced the discontinuation of Lindane Lotion 1%. The Companies have decided to stop manufacturing this product as of June 2, 2016.

Lycelle Head Lice Removal Kit Now Available without Rx

By May 04, 2016

Mission Pharmacal announced that Lycelle Head Lice Removal Kit (sodium laureth sulfate, isopropanol, citronellyl acetate, hypromellose, methyl salicylate, methylparaben, citric acid) is now available without a prescription.

Treatment-Resistant Lice Common Across the U.S.

By August 18, 2015

Treatment-resistant lice with one or more genetic mutations have been identified in at least 25 states, according to research presented at the 250th National Meeting & Exposition of the American Chemical Society (ACS).

Guidelines Updated for Lice Infestation Among Children

April 29, 2015

American Academy of Pediatrics also gives advice on best medicines to treat infestation

Natroba Now Approved for Younger Children with Head Lice

January 06, 2015

ParaPRO announced that the Food and Drug Administration (FDA) has approved an expanded age range for Natroba (spinosad) Topical Suspension, to include children 6 months of age and older who have pediculosis capitis (head lice).

Resistant Strain of Head Lice Prevalent in North America

March 12, 2014

Widespread use of pyrethrins- or pyrethroid-based products appears to have resulted in selection pressure for a highly-resistant strain of human head lice in North America.

Teledermatology Is Reliable for Initial Triage Consultations

February 18, 2014

Teledermatology is reliable for initial triage of patients, according to a study published online.

Single Topical Ivermectin Head Lice Treatment Very Effective

November 01, 2012

A single 10-minute, at-home treatment with topical ivermectin lotion eliminates head lice infestations in nearly all patients by the next day.

Sklice Lotion Now Available

August 21, 2012

Sanofi Pasteur announced that Sklice (ivermectin) Lotion, 0.5%, is now available for the treatment of head lice in patients 6 months of age and older.

Head Lice Beginning to Show Permethrin Resistance

June 05, 2012

Although live head lice obtained from school-aged children in Paris remain susceptible to the insecticide malathion, approximately 14% have been found to be resistant to permethrin, suggesting a strong basis for future insecticide resistance.

Sklice Lotion Approved for Head Lice

February 08, 2012

Sanofi announced that the FDA has approved Sklice (ivermectin lotion) 0.5% for the topical treatment of head lice in patients ≥6 months of age.

NDA Accepted for Ivermectin for Head Lice

June 07, 2011

Topaz Pharmaceuticals announced the FDA has accepted for filing the NDA for ivermectin, a topical cream used to treat head lice in children and adults.

Natroba topical suspension approved for head lice treatment

January 18, 2011

The FDA has approved Natroba (spinosad, from ParaPRO) topical suspension 0.9% for the treatment of head lice infestations in patients ≥4 years old.

Phase 3 study of ivermectin topical cream for the treatment of head lice

December 16, 2010

Topaz Pharmaceuticals announced the completion of two Phase 3 clinical trials that studied the use of ivermectin topical cream as a potential treatment for head lice.